Neurofeedback and Hyperbaric Oxygen Therapy: New Hope for TBI

Traumatic brain injury (TBI) is a leading cause of long-term disability and presents complex challenges for both patients and clinicians. A 2024 study by Peterson et al. explores a combined approach using neurofeedback and hyperbaric oxygen therapy (HBOT) to treat the lingering effects of severe TBI. This emerging research offers a new perspective on recovery, demonstrating how advanced therapies can significantly improve brain function and quality of life.

Neurofeedback operates through operant conditioning, training individuals to optimize their brainwave patterns using real-time EEG monitoring. HBOT, in contrast, delivers high levels of oxygen to damaged brain tissues to support healing and neuroplasticity. By combining these modalities, this case study offers hope for addressing cognitive and emotional deficits that conventional rehabilitation often fails to resolve.

The study follows a 33-year-old woman who, after suffering a severe TBI in 2018, underwent a 31-month course of neurofeedback and HBOT. By the end of treatment, her progress marked a remarkable shift in both physiological and functional markers—highlighting the powerful potential of these interventions in holistic brain rehabilitation.

Methods

This longitudinal case study explored the combined effects of neurofeedback and HBOT in the context of severe TBI. The patient received neurofeedback sessions 2 to 3 times per week, each lasting 30–60 minutes. The training targeted the left hemisphere—where the injury was located—by increasing alpha and beta activity while suppressing delta and theta, promoting cognitive recovery.

HBOT was administered in a monoplace chamber pressurized to 1.5–2.0 ATA with 100% oxygen. Over 300 sessions were completed, with treatments occurring up to five times weekly. This protocol aimed to increase oxygenation in hypoxic brain regions, stimulate neurogenesis, and reduce inflammation.

Quantitative EEG (qEEG) assessments were performed before and after treatment using a 19-electrode cap to monitor frequency-specific brainwave activity. Principal component analysis (PCA) was used to examine pre/post-treatment scores and highlight differences in regional activity.

Results

The patient showed significant improvements in cognitive, emotional, and functional domains. Initial qEEG data revealed elevated delta and theta waves—indicative of a slowed, dysregulated brain. Post-treatment recordings showed a healthier distribution of alpha and beta activity, correlating with enhanced executive function and emotional regulation.

PCA revealed a shift from simpler to more complex brainwave structures over the course of treatment. The most notable gains were seen in beta and gamma activity, associated with attention, memory, and higher-order processing. Behavioral measures such as the Disability Rating Scale (DRS) and Glasgow Outcome Scale Extended (GOSE) also documented significant improvements in daily tasks such as feeding, toileting, and communication.

Discussion

The integration of neurofeedback and HBOT offers a compelling treatment model for severe TBI. Their combined effects on cognitive restoration and emotional regulation underscore the importance of addressing the multifactorial nature of TBI symptoms.

Clinically, neurofeedback’s individualized nature—tailored through qEEG data—allows protocols to be adapted to each patient’s neurological profile. HBOT complements this by providing a physiological foundation for healing through enhanced oxygenation and cellular recovery.

Despite the success seen in this case, challenges remain. Persistent variability in alpha activity suggests ongoing emotional dysregulation and highlights the need to address anxiety and stress throughout recovery. Cognitive gains, while significant, are just one part of a larger, more complex journey that demands continuous support and flexibility in care.

Further research into the synergy between neurofeedback and HBOT could pave the way for optimized treatment protocols. When integrated into a multidisciplinary framework, these therapies may offer broad benefits—treating not only cognitive but also emotional and physical sequelae of TBI.

Brendan’s Perspective

This case study powerfully illustrates the potential of combining neurofeedback with HBOT for restoring brain function and improving quality of life after severe TBI. From a clinical neurofeedback standpoint, it reaffirms a key truth: neurofeedback’s greatest strength lies in its versatility, especially when embedded within a larger, personalized treatment strategy.

In practice, we often target specific EEG frequency bands depending on clinical presentation and qEEG assessment results:

• SMR training (12–15 Hz at Cz) can be useful for enhancing cognitive stability and reducing impulsivity.

• Posterior alpha enhancement (8–12 Hz at Pz or Oz) often supports sensory and visual recovery, often disrupted in TBI.

• Low-beta protocols (15–18 Hz at F3/F4) can, in many, rebuild cognitive engagement without exacerbating over-arousal.

However, what makes neurofeedback truly powerful is how well it integrates with a great many other therapeutic modalities—cognitive-behavioral therapy, mindfulness, breathing retraining, somatic practices, and, as shown here, HBOT.

But here’s the paradox: the more versatile neurofeedback becomes, the harder it is to study it rigorously—especially in combination with other interventions. Well-designed randomized controlled trials (RCTs) are rare. And while case studies like this are invaluable, offering rich clinical insights, they inherently limit generalizability.

To move forward, we need three major shifts:

1. Substantial investment in high-quality, large-scale research exploring both standalone and integrative neurofeedback approaches.

2. Unified clinical research guidelines that define EEG targets, protocol criteria, and success metrics with clarity and reproducibility.

3. Closer alignment between clinical practice and research design, ensuring that what’s being tested in trials reflects the complexities of real-world therapy—not overly simplified lab scenarios.

Without this foundation, we risk underutilizing a tool with enormous clinical potential. Neurofeedback, especially when combined with complementary therapies like HBOT, deserves to move from promising niche to standardized care—but it can’t get there without better science—and the science done in research needs to catch up to the applied science done in clinical practice.

Conclusion

The combined use of neurofeedback and HBOT offers a transformative model for treating severe TBI. With measurable gains in brain function and emotional regulation, this dual approach shows how emerging neuroscience can translate into real-world recovery.

But this is just the beginning. With deeper research, structured standards, and meaningful investment, we can shape a future where recovery from brain injury is no longer a hopeful exception—but a well-supported reality.

Reference

Peterson, T., et al. (2024). Long-Term Effects of Neurofeedback and Hyperbaric Oxygen Therapy on Traumatic Brain Injury: A Principal Component Analysis (PCA)-Based Secondary Analysis. Cureus, 16(11): e74305. https://doi.org/10.7759/cureus.74305